New Zealand markets closed

Bayer Aktiengesellschaft (BAYRY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.29-0.19 (-1.41%)
As of 1:04PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close13.48
Open13.36
Bid0.00 x 0
Ask0.00 x 0
Day's range13.21 - 13.39
52-week range11.65 - 17.34
Volume362,179
Avg. volume437,739
Market cap52.242B
Beta (5Y monthly)1.33
PE ratio (TTM)N/A
EPS (TTM)-0.81
Earnings dateN/A
Forward dividend & yield0.59 (4.41%)
Ex-dividend date28 Apr 2021
1y target est15.30
  • Business Wire

    Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Cavallo Ventures

    LEVERKUSEN, Germany & EMERYVILLE, Calif., September 14, 2021--Leaps by Bayer, the impact investment arm of Bayer AG, today announced that it has co-led a USD 15 million Series A investment round in agriculture and biotechnology innovator, Andes, with Cavallo Ventures. Other new investors Builders VC, Germin8, Accelr8 and Wilson Sonsini participated, alongside existing investors KdT Ventures and Endurance.

  • Bloomberg

    Bayer Unit Makes More Investments to Curb Synthetic Fertilizers

    (Bloomberg) -- Bayer AG just made its second investment in as many months in startups working to curb the use of synthetic fertilizers, a step that would help the agricultural industry -- a major polluter -- become more environmentally friendly.The industry giant, which owns agrochemical and biotechnology company Monsanto Co., said Tuesday one of its units co-lead a $15 million investment in Andes, a startup that treats seeds so plants can better draw nitrogen from the air instead of needing ene

  • Zacks

    Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal

    Bayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough.